SCHEMBL2282489

SCHEMBL2282489

NC(=O)CC[C@H](C(=O)O)N1C(=O)c2cccc([N+](=O)[O-])c2C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
ALDH1A1 P00352 2/20 0.51
MAPK1 P28482 2/20 0.51
KDM4E B2RXH2 1/20 0.51
TP53 P04637 1/20 0.51
GLA P06280 1/20 0.51
POLB P06746 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
HPGD P15428 1/20 0.51
ALOX12 P18054 1/20 0.51
NFKB1 P19838 1/20 0.51
APEX1 P27695 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TNF P01375 1/20 0.49
ATM Q13315 1/20 0.44
GAA P10253 2/20 0.42
CA4 P22748 2/20 0.42
CA1 P00915 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2168623 1.00 MEN1 (0.54) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL2282582 1.00 MEN1 (0.54) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL29790477 1.00 MEN1 (0.54) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL15930057 0.91 ALDH1A1 (0.64) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL2167750 0.91 ALDH1A1 (0.64) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL6255431 0.88 TNF (0.53) MEN1KMT2AALDH1A1KDM4ETNF
SCHEMBL6268629 0.86 ALDH1A1 (0.54) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL2168112 0.86 ALDH1A1 (0.51) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL2288486 0.86 ATM (0.46) MEN1KMT2AALDH1A1MAPK1KDM4E
SCHEMBL2278593 0.84 TNF (0.47) MEN1KMT2AALDH1A1MAPK1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266514-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2019-04-23 US disclosed
US-20180044318-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2018-02-15 US disclosed
US-9822093-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2017-11-21 US disclosed
US-20160297791-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2016-10-13 US disclosed
US-9394274-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2016-07-19 US disclosed
US-20140256950-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-09-11 US disclosed
US-8785644-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2014-07-22 US disclosed
EP-2380887-B1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORP (US) 2013-08-07 EP disclosed
EP-1907373-B1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2013-01-09 EP disclosed
EP-2380887-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds Celgene Corporation (US) 2011-10-26 EP disclosed
US-20110224440-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION 2011-09-15 US disclosed
US-7994327-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2011-08-09 US disclosed
EP-1907373-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2008-04-09 EP disclosed
WO-2007005972-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2007-01-11 WO disclosed
US-20070004920-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds CELGENE CORPORATION AN ORGNIZATION OF THE STATE NEW JERSEY (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224440-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS TNF, TRAF2, IL1A MEN1 4003/4885KMT2A 3715/4885ALDH1A1 245/4885
US-20160297791-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS TNF, TRAF2, IL1A MEN1 4003/4885KMT2A 3715/4885ALDH1A1 245/4885
US-10266514-B2 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds TNF, TRAF2, IL1A MEN1 4003/4885KMT2A 3715/4885ALDH1A1 245/4885
US-20070004920-A1 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds TNF, DHPS, IL1A MEN1 3805/4885KMT2A 3682/4885ALDH1A1 77/4885
US-20140256950-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS TNF, TRAF2, IL1A MEN1 4003/4885KMT2A 3715/4885ALDH1A1 245/4885
US-20180044318-A1 PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS TNF, TRAF2, IL1A MEN1 4003/4885KMT2A 3715/4885ALDH1A1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.